Successful Grant Application! Trince received a VLAIO R&D grant to support activities for further developing its novel intracellular delivery technology towards clinical cell-based therapeutic applications.
The project runs until April 2025 and has three main objectives:
- Successful engineering of human T cells with large effector molecules (plasmids, mRNA and CRISPR/Cas9 RNPs) while preserving T cell fitness and therapeutic efficacy,
- Develop a prototype device for automated high-throughput transfection of T cells based on Trince’s proprietary photoporation technology and,
- Successful internal and external evaluation of the automated high-throughput prototype device.
